A Phase 2 interventional study of Ibudilast and Placebo Oral Tablet in Methamphetamine-dependence, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Neuroinflammatory Diseases with a site in United States — 21 open to participants now, 26 under way, none of them phase 3. Neuroinflammatory Diseases · United States.
Among the 59 studies in Neuroinflammatory Diseases with a site in United States, this one has the largest enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2019, is one of 15 in phase 2, and was the 16th registered.
180 studies on the registry are indexed under Neuroinflammatory Diseases; 80 are open to participants now.
Browse Neuroinflammatory Diseases studies →21 of the 59 studies in Neuroinflammatory Diseases with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 50+
National Institute of Mental Health (NIMH) · Sites in United States
Ages 1 mo–100 yrs
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Washington University School of Medicine · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Neuroinflammatory Diseases studies recruiting now, 16 (30%) set no upper age limit and 24 (45%) stop at 75 or younger; 11 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 17 · Phase 3 1 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 44 across 113 interventional studies indexed under Neuroinflammatory Diseases.
Median enrollment 30 across the 38 interventional studies, 65 across the 21 observational. Of the 30 that completed or were terminated, 9 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 59 have an industry lead sponsor. The 10 most frequent:
VA Office of Research and Development is the lead sponsor of 1,771 studies on the registry; 392 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
VA Office of Research and Development has 2 studies filed under Neuroinflammatory Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Neuroinflammatory Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02435810National Institute of Neurological Disorders and Stroke (NINDS)Inflammatory and Infectious Diseases of the Nervous System | 2026-11-29 |
| NCT05020535Johns Hopkins UniversityBiomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) | 2026-11-30 |
| NCT05350774National Institute of Neurological Disorders and Stroke (NINDS)Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 | 2026-12-15 |
| NCT07651787University of OklahomaUsing Light Therapy for Mild Cognitive Impairment | 2026-12-31 |
| NCT07303933Penn State UniversityFemale Concussion Head Cooling | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 59 studies in Neuroinflammatory Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.
The investigators are interested to know if the study drug can help some symptoms that methamphetamine can cause, specifically inflammation in the brain. Inflammation has been shown to affect decision-making. The study drug has anti-inflammatory properties, however it is not yet known whether the drug will reduce inflammation in the brain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
Drug: Placebo Oral Tablet
Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
Drug: Ibudilast
Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
Ibudilast capsules will be orally ingested twice daily for 6 weeks.
Placebo capsules will be orally ingested twice daily for 6 weeks.
Effects of ibudilast on brain function as assessed by magnetic resonance imaging (MRI)
Pre and post differences in brain function will be assessed.
Time frame: 6 weeks
Effects of ibudilast on overall cognitive battery score.
Pre and post differences in overall cognitive battery score will be assessed.
Time frame: 6 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Oct 2025, 77 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibudilast
VA Office of Research and Development →